肉毒毒素治疗鼻炎:文献综述与变应性鼻炎后鼻壁注射研究
本文综述肉毒毒素在鼻炎中的应用,并报告一项单臂先导研究:10例中重度变应性鼻炎成人接受内镜下双侧鼻后外侧壁注射12.5单位Botox,TNSS从基线15.1降至2周7.6、4周7.7,RQLQ各域改善,2例轻度头痛。
要点
- 综述认为BTX对内在性和变应性鼻炎症状均有明确疗效且安全性良好。
- 单臂研究中TNSS从基线15.1降至2周7.6和4周7.7。
- 后鼻壁注射操作不适平均评分5.7/10,2例轻度头痛无需干预。
核心结论
- 基于文献综述,BTX对内在性和变应性鼻炎症状均显示明确疗效,安全性良好。
- 单剂后鼻壁注射显示良好疗效和作用持续时间,操作不适为中度。
研究设计与样本
- 单臂先导研究纳入10例明确屋尘螨过敏的中重度变应性鼻炎成人患者。
- 每例患者在内镜引导下于双侧鼻后外侧壁各注射12.5单位Botox。
主要发现
- 总体TNSS(最小0,最大20)均值从注射前15.1降至2周7.6和4周7.7。
- 症状亚量表中流涕改善最明显(4.0降至1.7),其次为喷嚏、鼻塞和鼻痒。
- RQLQ各生活质量域均显示改善。
- 2例受试者诉轻度头痛,无需任何医疗干预。
- 操作不适平均评分为5.7/10。
临床怎么用
- 文献综述提示BTX可用于内在性和变应性鼻炎的症状控制。
- 内镜下后鼻壁注射单剂Botox 12.5单位/侧可能作为变应性鼻炎的治疗选择。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current pharmacological management of allergic rhinitis (AR) varies in onset, duration, symptom control, and requires frequent administration. Single-dose botulinum toxin (BTX) has been documented in various trials as a treatment option in rhinitis. OBJECTIVE: We review the current literature on the use of BTX in rhinitis and investigate the efficacy and safety profile of a novel intranasal injection site for AR control. STUDY DESIGN: Single-arm pilot study. METHODS: Ten adult patients having moderate to severe AR with proven house dust-mite allergy were recruited. Each patient received 12.5 units of Botox injected to the posterior lateral wall of each side of the nose under endoscopic guidance. Immediate postprocedural discomfort and Total Nasal Symptom Score (TNSS) at 2 and 4 weeks were used as primary outcome measures. Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) was used as secondary outcome measure. RESULTS: Overall TNSS (minimum = 0; maximum = 20) showed an improvement from a mean of 15.1 (preinjection) to 7.6 (2 weeks) and 7.7 (4 weeks). Greatest effect was seen in subscales of rhinorrhea (4.0-1.7) followed by sneeze, nasal congestion, and itch. Mean discomfort of the procedure was scored 5.7 over 10. RQLQ scores similarly showed an improvement in all domains of quality of life. Two subjects complained of mild headache not requiring any medical intervention. CONCLUSION: Based on our review of current literature, BTX shows clear efficacy on symptoms of both intrinsic and allergic rhinitis, with a good safety profile. Single-dose posterior nasal injection demonstrates good efficacy and duration of action, with moderate discomfort. LEVEL OF EVIDENCE: 4. Laryngoscope, 127:2447-2454, 2017.
引用
- Zhang EZ, Tan S, Loh I, et al. Botolinum toxin in rhinitis: Literature review and posterior nasal injection in allergic rhinitis. Laryngoscope. 2017. PMID: 28681969. doi:10.1002/lary.26616
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。